Skip to main navigation
Skip to search
Skip to main content
Experts@Minnesota Home
Home
Profiles
Research units
University Assets
Projects and Grants
Research output
Datasets
Press/Media
Activities
Fellowships, Honors, and Prizes
Impacts
Search by expertise, name or affiliation
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers
Yan Wang
, Shijia Zhang
, Fengying Wu
, Jing Zhao
, Xuefei Li
, Chao Zhao
, Shengxiang Ren
, Caicun Zhou
Medicine - Hematology, Oncology, Transplant
Research output
:
Contribution to journal
›
Article
›
peer-review
62
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Keyphrases
Pemetrexed
100%
Lung Cancer
100%
Chemotherapy
100%
HER2-mutant
100%
HER2 mutation
60%
ROS1
60%
First-line Chemotherapy
40%
Lung Adenocarcinoma
40%
Adenocarcinoma
40%
EGFR mutation
40%
KRAS mutant
40%
ROS1 Rearrangement
40%
HER2-targeted Therapy
40%
Non-small Cell Lung Cancer (NSCLC)
20%
Locally Advanced Non-small Cell Lung Cancer (LA-NSCLC)
20%
Human Epidermal Growth Factor Receptor 2 (HER2)
20%
Clinical Practice
20%
Subgroup Analysis
20%
Targeted Drugs
20%
Unique Populations
20%
Objective Response Rate
20%
Progression-free Survival
20%
BRAF mutation
20%
Median Progression-free Survival
20%
ARMS-PCR
20%
Cancer-directed Therapy
20%
Selected Populations
20%
Oncogenic Driver Gene
20%
Pharmacology, Toxicology and Pharmaceutical Science
Chemotherapy
100%
Lung Cancer
100%
Epidermal Growth Factor Receptor
100%
Pemetrexed
100%
First-Line Chemotherapy
50%
Non Small Cell Lung Cancer
50%
Lung Adenocarcinoma
50%
Progression Free Survival
50%
Adenocarcinoma
50%
Carcinogenesis
25%
Medicine and Dentistry
Lung Cancer
100%
Pemetrexed
100%
Epidermal Growth Factor Receptor
100%
First-Line Chemotherapy
50%
Adenocarcinoma
50%
Lung Adenocarcinoma
50%
Non Small Cell Lung Cancer
50%
Progression Free Survival
50%
Subgroup Analysis
25%
Carcinogenesis
25%